Docon Technologies, a promoter of Thyrocare, sold a 10% stake (53.3 lakh shares) in the diagnostics chain for around ₹667.7 crore. Post sale, Docon’s holding drops from 70.98% to 60.93%, while institutional investors including mutual funds picked up the shares.
Glimpse:
Through open market transactions, Docon offloaded 10% of Thyrocare at an average price of ₹1,252.03 per share, raising ₹667.7 crore. The move draws in high-profile buyers like ICICI Prudential and Aditya Birla MF, while Docon retains majority control.
Docon Technologies, the promoter entity behind Thyrocare Technologies, has divested 53,32,860 equity shares representing a 10% stake in an open-market transaction valued at about ₹667.69 crore. The shares were sold at an average price of ₹1,252.03 each.
This stake sale reduces Docon’s promoter holding from 70.98% to 60.93%, while still retaining its majority position in Thyrocare. The block transaction saw participation from several institutional investors, such as ICICI Prudential MF, Aditya Birla Sun Life MF, HSBC Midcap Fund, HDFC MF, among others.
Market reaction was steady Thyrocare shares rose around 1.6% following the announcement, indicating confidence that the business fundamentals remain intact despite the promoter dilution. The move is viewed as a strategic capital raise providing liquidity to Docon (and by extension API Holdings), while maintaining control over Thyrocare
Analysts note that by selling only a portion of their holdings, promoter Docon balances unlocking value with preserving decision-making influence. The infusion of institutional capital may also help broaden Thyrocare’s investor base and support future growth plans.
“Despite offloading 10%, Docon continues to hold majority control this is a balanced move toward capitalizing value while staying committed to Thyrocare’s future.”
By
HB Team
